Prelude Capital Management’s Inovio Pharmaceuticals INO Stock Holding History

Prelude Capital Management’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-83	Closed	-$13.3K	–	2097
2020 Q1	$7K	Buy	+83	New	+$5.12K	﹤0.01%	1185
2019 Q3	–	Sell	-288	Closed	-$10K	–	1864
2019 Q2	$10K	Buy	+288	New	+$11.4K	﹤0.01%	1395
2017 Q4	–	Sell	-242	Closed	-$18K	–	1508
2017 Q3	$18K	Buy	242 +59	+32%	+$4.39K	﹤0.01%	1338
2017 Q2	$17K	Buy	+183	New	+$15.7K	﹤0.01%	1297
2014 Q4	–	Sell	-42	Closed	-$5K	–	2017
2014 Q3	$5K	Buy	+42	New	+$5.23K	﹤0.01%	1812

Other funds holding INO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Prelude Capital Management's INO Position: Q2 2020 in Review

Prelude Capital Management sold out of Inovio Pharmaceuticals (INO) in Q2 2020, closing a stake of 83 shares — an estimated $13.3K sold.

Prelude Capital Management first reported a position in INO in Q3 2014 and held it in 5 quarters. The position peaked at $18K in Q3 2017. 214 funds tracked by Wall St. Rank hold INO as of Q2 2020.

Prelude Capital Management reported no remaining Inovio Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
Prelude Capital Management sold 83 Inovio Pharmaceuticals shares in Q2 2020, an estimated $13.3K.
Prelude Capital Management first reported a position in Inovio Pharmaceuticals in Q3 2014 and held it in 5 quarters.
Prelude Capital Management's Inovio Pharmaceuticals position peaked at $18K in Q3 2017.
214 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2020.

Based on Prelude Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.